Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Net Margin (2016 - 2025)

Ani Pharmaceuticals' Net Margin history spans 15 years, with the latest figure at 11.13% for Q4 2025.

  • For Q4 2025, Net Margin rose 1673.0% year-over-year to 11.13%; the TTM value through Dec 2025 reached 8.74%, up 1202.0%, while the annual FY2025 figure was 8.74%, 1202.0% up from the prior year.
  • Net Margin for Q4 2025 was 11.13% at Ani Pharmaceuticals, down from 11.53% in the prior quarter.
  • Across five years, Net Margin topped out at 12.95% in Q1 2024 and bottomed at 39.93% in Q4 2021.
  • The 5-year median for Net Margin is 0.69% (2023), against an average of 5.41%.
  • The largest YoY upside for Net Margin was 3500bps in 2022 against a maximum downside of -3257bps in 2022.
  • A 5-year view of Net Margin shows it stood at 39.93% in 2021, then surged by 88bps to 4.93% in 2022, then skyrocketed by 112bps to 0.57% in 2023, then plummeted by -1085bps to 5.61% in 2024, then soared by 299bps to 11.13% in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Net Margin are 11.13% (Q4 2025), 11.53% (Q3 2025), and 3.85% (Q2 2025).